CI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cigna Group (CI) does not present a strong buy opportunity for a beginner, long-term investor at this moment. While the stock has seen positive price movement recently and has favorable analyst ratings, the company's financial performance shows declining net income, EPS, and gross margin. Additionally, there are no strong proprietary trading signals, and the options data suggests a neutral to slightly bullish sentiment. Given the investor's profile and the lack of immediate strong catalysts, holding off on a purchase is advisable.
The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 58.836, and moving averages are converging, suggesting no strong directional bias. The stock is trading near its resistance level (R1: 278.275), which could limit short-term upside potential.
The company's efforts to address PBM reform and FTC settlements are seen as clearing events that could lead to long-term growth.
Declining financial performance in Q4 2025, including a 13.34% drop in net income and an 11.31% drop in EPS. Concerns over Medicare Advantage Rate changes in 2027, which could introduce political risks to the sector.
In Q4 2025, revenue increased by 10.39% YoY to $72.47 billion. However, net income declined by 13.34% YoY to $1.23 billion, EPS dropped by 11.31% to 4.55, and gross margin decreased by 10.65% to 8.22%.
Analysts are generally positive on Cigna, with multiple firms maintaining Buy or Overweight ratings and raising price targets. Recent upgrades highlight the company's ability to address regulatory challenges and position itself for long-term growth.
